Adalimumab, a fully humanized monoclinal anti-TNF-α antibody, has been approved for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older by the Food and Drug Administration. This evidence concerns the gene TNF and panuveitis.